Thomas Malley, Director at Kiniksa Pharmaceuticals International, plc (KNSA), sold 355,538 shares at $33.32 ($11.7M) on 2025-08-13, disclosed to the SEC on 2025-08-14.
Open-market sale of $11.7M KNSA by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.40 | 49,407 | $1.6M | 13.7% |
| 2 | $32.40 | 49,407 | $1.6M | 13.7% |
| 3 | $33.32 | 50,129 | $1.7M | 14.3% |
| 4 | $33.32 | 50,129 | $1.7M | 14.3% |
| 5 | $33.09 | 78,233 | $2.6M | 22.1% |
| 6 | $33.09 | 78,233 |
| $2.6M |
| 22.1% |
| Total | $32.96 avg | 355,538 | $11.7M | 100% |
| Filing → |
| KURA | BUY | 2015-12-17 | $400K | — | Filing → |
| OVAS | BUY | 2015-04-09 | $143K | — | Filing → |
| OVAS | BUY | 2015-01-15 | $1.8M | — | Filing → |